Celldex

Celldex is scheduled to report fourth-quarter earnings before the market opens on March 3, 2011.

Speculation On A Monster Rebound, Higher Oil Andrew Wilkinson 2011

Shares in Celldex increased as much as 12.75% during the session to hit an intraday high of $3.89 on reports of unconfirmed takeover chatter.

Speculation On A Monster Rebound, Higher Oil Andrew Wilkinson 2011

Activity in Celldex options is confined almost entirely to calls today, with heavy volume accumulating in the front month.

Speculation On A Monster Rebound, Higher Oil Andrew Wilkinson 2011

Celldex Therapeutics plunged 30% to a new 52 week low on Friday, after partner Pfizer terminated its agreement with the company surrounding its cancer vaccine program, saying the program is no longer a strategic priority.

Quiksilver Tarnishes, Seachange Sinks 2010

In 2009 drug developer Celldex Therapeutics of Needham, Mass. bought the remnants of Curagen for just $95 million.

Gene Machine Matthew Herper 2010

Celldex Therapeutics plunged 1.25, or 26%, to 3.53, after saying it will continue to develop a brain-tumor vaccine alone after large-cap

Small Stocks Extend Their Winning Run 2010

Helping drag down the group were shares of Aspenbio Pharma, down about 54.1% and shares of Celldex Therapeutics down about 15.1% on the day.

Drug Delivery Shares Running Late Monday 2010

Celldex Therapeutics plunged 30% to a new 52 week low on Friday, after partner Pfizer terminated its agreement with the company surrounding its cancer vaccine program, saying the program is no longer a strategic priority.

Quiksilver Tarnishes, Seachange Sinks 2010

Celldex shares plunged as much as 30% to a new 52 week low today, after partner Pfizer

General Contractors, Diagnostic Substances Fall Behind 2010

Celldex sees stock woes with deal loss, growing investor industry skepticism Follow this company that will put $213,528 back into the state’s Medicaid Program, Wisconsin Attorney General J.B. Van Hollen said Friday.

unknown title 2011